Amarin announced a new marketing strategy for the company’s Vascepa drug in the United States, starting with reducing the Irish-American biopharmaceutical firm’s sales rep numbers by more than 50 percent.
Grünenthal agreed to acquire the European rights (excluding Spain and the UK) to AstraZeneca’s Crestor (rosuvastatin) and its associated brands for a total consideration of up to $350 million.
Amarin Corporation plc announced the launch of True To Your Heart, an educational campaign to help people learn more about cardiovascular disease and how to better protect against persistent cardiovascular risk.
Amarin Corp. Plc’s fish oil-derived drug and potential blockbuster Vascepa received a largely positive review from FDA staffers.
Many of the drugs that are sold over-the-counter (OTC) began life as prescription medications. Anti-ulcer/heartburn drugs such as the histamine H2 antagonist, Zantac, and the proton-pump inhibitor, Prilosec, were first […]
